摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

NU 1038 | 172462-92-9

中文名称
——
中文别名
——
英文名称
NU 1038
英文别名
3-butoxy-benzoic acid amide;3-Butoxy-benzoesaeure-amid;3-butoxybenzenecarboxamide;3-butoxybenzamide
NU 1038化学式
CAS
172462-92-9
化学式
C11H15NO2
mdl
MFCD07158970
分子量
193.246
InChiKey
DSCIKRRACNLYCA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.363
  • 拓扑面积:
    52.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC AMIDES AS KINASE INHIBITORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE KINASE
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2014125444A1
    公开(公告)日:2014-08-21
    Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    揭示了具有式(I)的化合物,其中X、Y、Z1、Z2、Z3、Z4、R5、RA、m、A、L和B如本文所定义,并公开了制备和使用这些化合物的方法。
  • [EN] PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRODUCTION DE DÉRIVÉS DE 2-[2-(PHÉNYL)ÉTHYLAMINO]ALCANEAMIDE SUBSTITUÉS
    申请人:NEWRON PHARM SPA
    公开号:WO2020212227A1
    公开(公告)日:2020-10-22
    The present invention relates to a new process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives of the following formula (I), in particular 2-[2-(3-butoxyphenyl)-ethylamino]-N,N-dimethylacetamide in high yields with very high chemical purity. The invention relates to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof:
    本发明涉及一种用于生产以下式(I)的取代2-[2-(苯基)乙基氨基烷酰衍生物的新工艺,特别是高产率、化学纯度非常高的2-[2-(3-丁氧基苯基)-乙基氨基]-N,N-二甲基乙酰胺。该发明涉及一种制备式(I)化合物或其药用可接受盐的工艺:
  • ANTAGONISTS OF SNS SODIUM CHANNELS
    申请人:Hamlyn Richard
    公开号:US20100105651A1
    公开(公告)日:2010-04-29
    Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents, formula (I): R 1 represents: (a) -L-A or -L′-A′ wherein L represents a bond or a C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety, A represents a phenyl, 5- to 10-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 10-membered heterocyclyl group, L′ represents a C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety, and A′ represents -Het-A or —X-A wherein Het represents —O—, —S— or —NR 1 —, and X represents —CO—, —SO—, —SO 2 —, —CO—O—, —CO—S—, —CONR 1 —, —O—CO—, —S—CO— or —NR 1 —CO—, wherein R 1 represents hydrogen or C 1 -C 6 alkyl; (b) -L-CR(A)(A′) or -L-CR(A)(L-A) wherein R is hydrogen or C 1 -C 4 alkyl, A′ is as defined above, each L is the same or different and is as defined above and each A′ is the same or different and is as defined above; (c) -L-A-A′ or -L-A-L-A wherein A′ and L are as defined above and each A is the same or different and is as defined above; or (d) -A-Z-A wherein Z is -Het-L′-, —X-L′-, -L′-Het- or -L′-X—, wherein Het, L′ and X are as defined above and each A is the same or different and is as defined above; J represents —NR S —, —O— or a direct bond; R 5 represents hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl; R 4 is represents hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl; and either R represents -L-A, -L-A′, -L-A-A′, -L-A-L-A, -L-CR(A)(L-A), -L-CR(A)(A′) or -L-CR(A)(L″) wherein L″ is -Het-L′, —CONH 2 or —CO 2 H, and wherein A′, Het, X and R are as defined above, each L is the same or different and is as defined above, each A is the same or different and is as defined above and R 3 represents hydrogen, C 1 -C 6 alkyl C 2 -C 6 alkynyl or (CO)-L′, wherein L is as defined above or R 2 and R 3 form, together with the nitrogen to which they are attached, a 5- to 10-membered heteroaryl or 5- to 10-membered heterocyclyl ring.
    公式(I)的化合物及其药学上可接受的盐被发现是SNS钠通道的拮抗剂。因此,它们可用作镇痛和神经保护剂,公式(I):R1表示:(a)-L-A或-L′-A′,其中L表示键或C1-C6烷基,C2-C6烯基或C2-C6炔基基团,A表示苯基,5-至10-成员杂环芳基,C3-C6环烷基或5-至10-成员杂环基团,L′表示C1-C6烷基,C2-C6烯基或C2-C6炔基基团,A′表示-Het-A或—X-A,其中Het表示—O—,—S—或—NR1—,X表示—CO—,—SO—,—SO2—,—CO—O—,—CO—S—,—CONR1—,—O—CO—,—S—CO—或—NR1—CO—,其中R1表示氢或C1-C6烷基;(b)-L-CR(A)(A′)或-L-CR(A)(L-A),其中R为氢或C1-C4烷基,A′如上所定义,每个L相同或不同,如上所定义,并且每个A′相同或不同,如上所定义;(c)-L-A-A′或-L-A-L-A,其中A′和L如上所定义,每个A相同或不同,如上所定义;或(d)-A-Z-A,其中Z为-Het-L′-,—X-L′-,-L′-Het-或-L′-X—,其中Het,L′和X如上所定义,每个A相同或不同,如上所定义;J表示—NRS—,—O—或直接键;R5表示氢,C1-C6烷基,C2-C6烯基或C2-C6炔基;R4表示氢,C1-C6烷基,C2-C6烯基或C2-C6炔基;而R表示-L-A,-L-A′,-L-A-A′,-L-A-L-A,-L-CR(A)(L-A),-L-CR(A)(A′)或-L-CR(A)(L″),其中L″为-Het-L′,—CONH2或—CO2H,而A′,Het,X和R如上所定义,每个L相同或不同,如上所定义,每个A相同或不同,如上所定义,而R3表示氢,C1-C6烷基,C2-C6炔基或(CO)-L′,其中L如上所定义,或R2和R3共同形成与它们附着的氮原子相连的5-至10-成员杂环芳基或5-至10-成员杂环基团。
  • ANTIBACTERIAL AGENTS
    申请人:Brown David Ryall
    公开号:US20100173933A1
    公开(公告)日:2010-07-08
    Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R 1 )— or ═N—; R 1 is hydrogen or an optional substituent and R 2 is hydrogen, methyl, or fluorine; or R 1 and R 2 taken together are —CH 2 —, —CH 2 CH 2 —, —O—, or, in either orientation, —O—CH 2 — or —OCH 2 CH 2 —; R 3 is a radical of formula -(Alk 1 ) m -(Z) p -(Alk 2 ) n -Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(═O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk 1 and Alk 2 are optionally substituted C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, or —N(CH 2 CH 3 )—; and Q is hydrogen, halogen, nitrile, or hydroxyl or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms.
    化学式为(I)的化合物具有抗菌活性:其中R代表氢或1、2或3个可选取代基;W是═C(R1)-或═N-;R1是氢或可选取代基,R2是氢、甲基或氟;或R1和R2一起取-CH2-、-CH2CH2-、-O-,或者,在任何方向上,取-O-CH2-或-OCH2CH2-;R3是公式-(Alk1)m-(Z)p-(Alk2)n-Q的基团,其中m、p和n独立地为0或1,但至少有一个为1,Z是-O-、-S-、-S(O)-、-S(O2)-、-NH-、-N(CH3)-、-N(CH2CH3)-、-C(═O)-、-O-(C═O)-、-C(═O)-O-,或具有3至6个环原子的可选取代的单环碳环或杂环基团;或具有5至10个环原子的可选取代双环杂环基团;Alk1和Alk2是可选取代的C1-C6烷基、C2-C6烯基或C2-C6炔基基团,可以以-O-、-S-、-S(O)-、-S(O2)-、-NH-、-N(CH3)-或-N(CH2CH3)-结尾或被中断;Q是氢、卤素、腈或羟基,或具有3至6个环原子的可选取代的单环碳环或杂环基团;或具有5至10个环原子的可选取代的双环杂环基团。
  • Inhibitors of glucocorticoid receptor translocation
    申请人:Sanford Burnham Prebys Medical Discovery Institute
    公开号:US10272074B2
    公开(公告)日:2019-04-30
    Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.
    本文提供的是包含所述化合物的化合物和药物组合物。所述化合物和组合物可用作糖皮质激素受体(GR)转运的调节剂。此外,所述化合物和组合物还可用于治疗涉及下丘脑-垂体-肾上腺(HPA)轴的疾病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐